59% were diabetic, 44% hypertensive, 33% smokers and 26% hyperlipidaemic. 53% of the patients had ≤2 of these risk factors. There was no difference in age, sex, BMI, number of HCC’s or other metabolic risk factors between the cirrhotic and non-cirrhotic patients. Non-cirrhotics

had a significantly larger mean tumour diameter than cirrhotics (p = 0.041) and were more likely to have HCC outside of Milan criteria for transplantation (p = 0.034). Multivariate analysis did not identify any other patient characteristics that predicted size of hepatomas, but having diabetes (p = 0.03) or more than 2 risk factors (p = 0.03) correlated with having more numerous HCCs. Conclusions: This study demonstrates that HCC can develop in NAFLD without cirrhosis or obesity; and tumours in non-cirrhotics

are GW-572016 price larger conferring a poorer prognosis. The fact that smaller HCC were detected in the cirrhotic patients is likely due to formal HCC screening in this patient group. Thus, urgent studies are needed to clarify the role of HCC screening in non-cirrhotic NAFLD. T HONG,1 A THOMPSON,1 P GOW,2 M FINK,8 M RYAN,1 A DEV,3 I KRONBORG,4 N ARACHCHI,4 J LUBEL,5,9 A NICOLL,6 S ROBERTS,7 P DESMOND,1 S BELL1 With the Melbourne collaboration for the study of hepatocellular Selleck ATM/ATR inhibitor carcinoma (MESH) Departments of Gastroenterology & Hepatology, 1St Vincent’s Hospital, Melbourne, Australia. 2The Austin Hospital, Melbourne, Australia. 3Monash Medical Centre, Melbourne, Australia. 4Western Health, Melbourne, Australia. 5Eastern Health, Melbourne, Australia. 6The Royal Melbourne Hospital, Melbourne, Australia. 7The Alfred Hospital, Melbourne, Australia., 8Department of

Surgery, The Austin Hospital, Melbourne, Australia. Background: Recent studies suggest that the incidence of hepatocellular carcinoma (HCC) is rising rapidly. Australian epidemiological data are currently derived from cancer registries, which classify HCC according to histology. However, HCC is now a radiological diagnosis, with histology reserved for a minority of cases. Cancer registry data may therefore underestimate the true incidence of HCC. We have therefore performed the first population-based Niclosamide study of HCC incidence in Australia using current diagnostic criteria. Method: New diagnoses of HCC were prospectively collected between July 2012 and June 2013 at all tertiary hospital services in Melbourne. Cases were identified using capture-recapture methodology from multiple sources including public hospital HCC multi-disciplinary meetings, medical coding, radiology, pathology and pharmacy databases. Private gastroenterologists and hepato-pancreato-biliary surgeons were surveyed to confirm that all private cases were referred to one of the participating centres for discussion, radiology or surgery. Case definition was based on AASLD clinico-radiological criteria or histological verification.